

Glycoengineering of Therapeutic Antibodies

C. Klein¹

¹ Expert Scientist, Roche Glycart AG, Schlieren/Switzerland

Antibody dependent cellular cytotoxicity (ADCC) is the process of lysis of (tumor) target cells by immune effector cells. It requires the simultaneous binding of an antibody to a cell surface receptor on the target cell and via the Fc region of the antibody to the FcγRIIIa receptor on immune effector cells such as NK cells or macrophages/monocytes. Binding of the antibody to target and immune effector cells results in the cross-linking of FcγRIIIa with subsequent activation of FcγRIIIa signaling and release of proteins mediating the killing of the target cells such as perforin and of proteases such as granzymes. ADCC has been established as an important mode of action of therapeutic antibodies such as rituximab/MabThera (targeting CD20), cetuximab/Erbix (targeting EGFR) and trastuzumab/Herceptin (targeting HER2) which are approved for the treatment of various cancers. Translational research on rituximab and cetuximab has established that the response to therapeutic antibodies in patients can be influenced by the FcγRIIIa-158V/F polymorphism. This polymorphism results in the expression of a high affinity FcγRIIIa receptor (158V) and a low affinity FcγRIIIa receptor (158F) on immune effector cells and impacts the capability of antibodies to mediate ADCC [1–7]. We have recently developed a so-called GlycoMab technology that enhances the affinity of therapeutic antibodies for both the high and low affinity FcγRIIIa receptors through the introduction of a bisecting N-acetyl-glucosamine residue in the carbohydrate chain of the Fc region of the antibodies. The introduction of this bisecting N-acetyl-glucosamine moiety in the carbohydrate chain results in a steric interference with core fucosylation of the carbohydrate. This process and other approaches resulting in the afucosylation of therapeutic antibodies are known as “antibody glycoengineering”. We and others have demonstrated that glycoengineering and lack of the core fucose residue results in an up to 50-fold enhanced affinity of human IgG1 antibodies for the human FcγRIIIa receptors, and this subsequently results in an up to 100-fold enhanced ADCC induction (potency). Recently, we have demonstrated the structural basis of the enhanced affinity of afucosylated Fc regions for FcγRIIIa by X-ray crystallography. These studies provide a structural explanation for the high affinity and FcγRIIIa specificity of glycoengineering as opposed to other technologies used for Fc-engineering such as the introduction of mutations in the Fc region that also affect binding to other FcγRs [8–15]. Roche is currently investigating three therapeutic glycoengineered antibodies with optimized immune effector function targeting CD20, EGFR and HER3 in different phases of clinical trials. Obinutuzumab (GA101, RG7159) is a type II, anti-CD20 GlycoMab monoclonal antibody that was designed to mediate enhanced direct and immune effector cell-mediated cell killing as compared to rituximab. In addition to enhanced ADCC, due to its type II characteristics, GA101 exhibits en-

hanced direct cell death induction with a concomitant reduction of CDC. In NHL animal models GA101 demonstrated a superior efficacy in terms of tumor growth inhibition and survival compared to type I CD20 antibodies such as rituximab and ofatumumab, including the induction of complete tumor remission. In non-human primates GA101 induces superior and profound B cell depletion in lymphoid tissues compared to rituximab. In Phase I/II clinical trials GA101 showed promising activity in heavily pretreated NHL patients. GA101 is currently being investigated in pivotal clinical trials in B-CLL, iNHL and DLBCL in combination with chemotherapy, head-to-head with rituximab-based regimens and in Rituximab-refractory iNHL as well as in various Phase II clinical trials. GA101 was the first glyco- and Fc-engineered antibody to enter clinical trials and is now the most advanced glyco- and Fc-engineered antibody in clinical trials in the world [16–24].

GA201 (RG7160) is a second anti-EGFR GlycoMab monoclonal antibody that is currently being investigated in Phase II clinical trials. It was designed to combine potent EGFR signaling inhibition with enhanced ADCC induction. In xenograft models GA201 demonstrated superior activity compared to cetuximab and panitumumab. Hence, GA201 has the potential to show clinical activity in patients with solid tumors. Phase I clinical testing in heavily pretreated patients with advanced solid tumors demonstrated a manageable toxicity profile. Evidence of anti-tumor activity was also seen, especially in patients with colorectal cancer, including a number of patients who had previously received cetuximab and/or panitumumab (1 CR, 2 PR). Interestingly, one of the partial responses was reported in a tumor-harboring a k-ras mutation. GA201 is currently undergoing Phase II clinical trials in CRC and NSCLC in combination with chemotherapy as well as a neo-adjuvant biomarker study in HNSCC [25].

Conflict of Interest: The author is employed by Roche Glycart AG.

References

- 1 Wang SY, Weiner G. Complement and cellular cytotoxicity in antibody therapy of cancer. *Expert Opin Biol Ther* 2008; 8: 759–768
- 2 Cartron G, Trappe RU, Solal-Celigny P et al. Interindividual variability of response to rituximab: from biological origins to individualized therapies. *Clin Cancer Res* 2011; 17: 19–30
- 3 Cartron G. FCGR3A polymorphism story: a new piece of the puzzle. *Leuk Lymphoma* 2009; 50: 1401–1402
- 4 Dall'Ozzo S, Tartas S, Paintaud G et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. *Cancer Res* 2004; 64: 4664–4669
- 5 Cartron G, Watier H, Golay J et al. From the bench to the bedside: ways to improve rituximab efficacy. *Blood* 2004; 104: 2635–2642
- 6 Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. *Blood* 2002; 99: 754–758
- 7 Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. *Nat Rev Immunol* 2010; 10: 317–327
- 8 Ferrara C, Grau S, Jager C et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose. *Proc Natl Acad Sci U S A* 2011; 108: 12669–12674
- 9 Ferrara C, Brunker P, Suter T et al. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-

- N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. *Biotechnol Bioeng* 2006; 93: 851–861
- 10 Ferrara C, Stuart F, Sondermann P *et al.* The carbohydrate at Fcγ3R-IIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. *J Biol Chem* 2006; 281: 5032–5036
 - 11 Schuster M, Umana P, Ferrara C *et al.* Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering. *Cancer Res* 2005; 65: 7934–7341
 - 12 Ashraf SQ, Umana P, Mossner E *et al.* Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis. *Br J Cancer* 2009; 101: 1758–1768
 - 13 Umana P, Jean-Mairet J, Moudry R *et al.* Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. *Nat Biotechnol* 1999; 17: 176–180
 - 14 Yamane-Ohnuki N, Satoh M. Production of therapeutic antibodies with controlled fucosylation. *MAbs* 2009; 1: 230–236
 - 15 Mori K, Iida S, Yamane-Ohnuki N *et al.* Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies. *Cytotechnology* 2007; 55: 109–114
 - 16 Honeychurch J, Alduaij W, Azizyan M *et al.* Antibody-induced non-apoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species dependent pathway. *Blood* 2012
 - 17 Jak M, van Bochove GG, Reits EA *et al.* CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101. *Blood* 2011; 118: 5178–5188
 - 18 Niederfellner G, Lammens A, Mundigl O *et al.* Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. *Blood* 2011; 118: 358–367
 - 19 Alduaij W, Ivanov A, Honeychurch J *et al.* Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. *Blood* 2011; 117: 4519–4529
 - 20 Bologna L, Gotti E, Manganini M *et al.* Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. *J Immunol* 2011; 186: 3762–3769
 - 21 Dalle S, Reslan L, Besseyre de Horts T *et al.* Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. *Mol Cancer Ther* 2011; 10: 178–185
 - 22 Patz M, Isaeva P, Forcob N *et al.* Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. *Br J Haematol* 2011; 152: 295–306
 - 23 Pievani A, Belussi C, Klein C *et al.* Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies. *Blood* 2011; 117: 510–518
 - 24 Mossner E, Brunker P, Moser S *et al.* Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. *Blood* 2010; 115: 4393–4402
 - 25 Paz-Ares LG, Gomez-Roca C, Delord JP *et al.* Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. *J Clin Oncol* 2011; 29: 3783–3790

Bibliography

DOI <http://dx.doi.org/10.1055/s-0032-1324900>
 Arzneimittelforschung 2012; 62, Suppl. 1: S4–S5
 © Georg Thieme Verlag KG Stuttgart · New York ·
 ISSN 0004-4172